A Translational Scientist’s Guide to World-Class Collaboration
Luis A. Diaz Jr, MD, is world renowned as a scientist and leader, but his greatest contribution to the world of cancer care might be as a collaborator and mentor.
Luis A. Diaz Jr, MD, is world renowned as a scientist and leader, but his greatest contribution to the world of cancer care might be as a collaborator and mentor.
Erin Frances Cobain, MD, highlights the current role of endocrine therapy and CDK4/6 inhibitors in HR-positive, HER2-negative metastatic breast cancer.
OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.
Rohan Garje, MD, discusses considerations when choosing between FDA-approved PARP inhibitor–based combinations for patients with mCRPC.
The findings of this cohort study suggest that approximately two-thirds of patients with aUC did not receive second-line treatment. Most first-line treatments do not include…
Premal Thaker, MD, MS, discusses how the RAMP-201 trial paved a way for the RAMP-301 trial of avutometinib/defactinib in low-grade serous ovarian cancer.
No significant difference in time to treatment was found between White and Black patients with bladder cancer, but there remained a difference in treatment outcomes.
David A. Braun, MD, PhD, highlights recent data focused on nivolumab plus cabozantinib in patients with non–clear cell renal cell carcinoma.
UW Health experts advocate for more women in leadership positions and discuss the need to cultivate diversity to reduce disparities in cancer care.
Angela Jia, MD, PhD, discusses the current standing of metastasis-directed radiotherapy in prostate cancer and identifies some lingering questions surrounding the modality.
Robert Wang, MD, discusses the presently limited utility of using molecular imagining with quantitative thresholds in distinguishing RCC from oncocytic renal masses.